the essential target for ablation.
However, we have the feeling that both endocardial and epicardial ablation of all abnormal signals could be more beneficial even though the studied cohort consisted of patients with ischemic heart disease. Unfortunately, epicardial ablation was performed only in a minority of the patients in the substrate-based ablation group. The possible benefit of combined endocardial and epicardial ablation of abnormal signals should be investigated in future trials. On the other side, even though the overall procedure duration between both groups was comparable, the mean radiofrequency time was expectedly longer in the substrate-ablation group, which raises concerns about myocardial stunning, fluid overload, and hemodynamic deterioration that can blunt the benefits of an achieved electrical stability.
Our biggest concern is the definition for "abnormal We also disagree about their concern on the definition of "abnormal potentials." This is well characterized in the literature and there is nothing "magic" about it (3, 4) . In addition, high amplitude delayed and complex electrograms can be found in the border zone. In this respect, most of the present series on ischemic cardiomyopathy, including one from the Leipzig group (5), concentrate their lesions along the scar border.
In regards to the need of endo-epicardial homogeneization of the scar, we would like to clarify that A U G U S T 9 , 2 0 1 6 : 6 6 5 -7 1 the 2012 paper excluded patients with coronary artery bypass graft (CABG) and showed that the need of epicardial ablation in patients without CABG appeared higher than previously reported. In the randomized trial, patients with CABG were included and the possibility of epicardial ablation was lower.
To conclude, although we consider the authors' appeal of interest, we would like to reinforce the concept that no data in regards to their concern are available and that the VISTA randomized trial confirms the validity of substrate-based ablation as a better way to perform ischemic VT ablation. We can certainly say that the present one is safe and efficacious and therefore valid not only "A PRIMA
VISTA."
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